The MELISA Technology Platform

Precision Diagnostics, Redefined

MELISA (Microdroplet ELISA) is a revolutionary platform that transforms traditional immunoassays by miniaturizing and multiplexing ELISA and CLIA diagnostics. By using proprietary microdroplet printing technology, MELISA enables multiple biomarker detections within a single well of a 96-well plate—drastically reducing reagent use and cost, while preserving assay sensitivity and specificity.

Key Innovations

• Microdroplet Multiplexing: Ultra-precise droplet printing deposits nanoliter-scale volumes, allowing many distinct detection spots per well.

• Custom Hardware: MELISA’s in-house developed pneumatic printer and high-resolution optical reader offer full automation and superior cost-efficiency.

• Smart Analysis: Integrated computer vision and statistical software deliver accurate, automated result quantification.

Advantages

• Dramatic Cost Reduction: Up to 90% savings in reagent and material use, lowering test costs for healthcare providers and patients.

• Streamlined Workflow: Multiple tests are completed with a single sample, reducing labor, reagents, and turnaround time.

• Global Accessibility: Designed to bring high-quality diagnostics to underserved regions through scalable, affordable solutions.

Market-Ready & Pipeline Products

• Ready: Dengue NS1 Multiplex Typing Kit (India launch, mid-2026)

• In Development:

  • Hepatitis B Four-Item Multiplex ELISA

  • Blood Bank Screening Panel

  • HIV/STD Multiplex

  • Tumor Marker Panel

Collaborations & Services

MELISA partners with biotech firms, academic labs, and diagnostic developers to:

• Adapt assays to microdroplet multiplexing

• Deploy proprietary instruments and software

• Co-develop and license new diagnostic kits